GLP-1 medications and PCOS: what the evidence actually shows

Semaglutide and tirzepatide are being prescribed to women with PCOS at rapidly rising rates. Here is an honest look at what these drugs can and cannot do, and what to ask your doctor before starting one. , -

GLP-1 receptor agonists are not approved to treat polycystic ovary syndrome, but they are increasingly prescribed off-label to women with PCOS who also have obesity or type 2 diabetes. The strongest evidence supports their use for weight loss and improving insulin resistance, both of which can ease some PCOS symptoms as a secondary effect. Benefits for hormonal and reproductive symptoms are real but less certain, and they vary considerably from person to person. If you have PCOS and are wondering whether one of these medications might help you, the honest answer is: possibly, for some things, and it depends on your specific situation.

GLP-1 receptor agonists are a class of medications that mimic glucagon-like peptide-1, a hormone naturally released by the gut after eating. They work by stimulating insulin release in response to blood sugar, slowing gastric emptying, and reducing appetite through signals to the brain. The result is lower blood sugar, reduced hunger, and, for most people, substantial weight loss. The medications most relevant to PCOS discussions are:

Semaglutide, sold as Ozempic (approved for type 2 diabetes) and Wegovy (approved for obesity). Available as a weekly injection or, in one formulation, as a daily oral tablet.

Tirzepatide, sold as Mounjaro (approved for type 2 diabetes) and Zepbound (approved for obesity). A weekly injection that targets both GLP-1 and GIP receptors, producing somewhat stronger effects on gastric emptying and weight loss than semaglutide.

Women with PCOS may already be familiar with metformin, the standard metabolic treatment for the condition for decades. Metformin improves insulin sensitivity primarily by reducing glucose production in the liver. GLP-1 receptor agonists work through different mechanisms and generally produce greater weight loss, but they also come with higher costs, different side effect profiles, and far less long-term data in PCOS specifically.

Prescribing has increased dramatically. According to data from Truveta, which analyzed records from approximately 1.7 million female patients, the rate of GLP-1 prescriptions among women with PCOS rose from 2.4% in 2021 to 17.6% in 2025, a more than sevenfold increase in four years. Nearly all of those prescriptions (97.8%) were written for women who also had obesity or type 2 diabetes. Clinicians are not yet prescribing these medications for PCOS as a standalone indication. They are prescribing them for metabolic conditions that coexist with PCOS, and women with PCOS are benefiting as a result. These remain off-label prescriptions for PCOS. No regulatory body, including the FDA, has approved GLP-1 receptor agonists for this indication. The rise in prescribing reflects both the broader surge in GLP-1 use across medicine and growing clinical recognition that metabolic management is central to PCOS care.

The evidence is strongest here. Weight and body composition. Meta-analyses of randomized controlled trials show that GLP-1 receptor agonists produce significant reductions in body weight, BMI, and waist circumference in women with PCOS. Even modest weight loss can reduce androgen levels and improve menstrual regularity in women whose PCOS is metabolically driven. Insulin resistance. Studies consistently show improvements in fasting insulin levels, HOMA-IR (a standard measure of insulin resistance), and blood sugar response during glucose tolerance testing. For women with PCOS whose symptoms are tied to insulin resistance, this is clinically relevant. Lipids. Effects on cholesterol are more modest and less consistent. HDL cholesterol may decrease slightly, though the clinical significance is unclear. Effects on LDL and total cholesterol vary across studies. Blood pressure. Some improvements have been reported, but the evidence in PCOS specifically is limited. Confidence is high for weight and insulin outcomes. For cardiovascular markers, it is moderate.

The metabolic picture is relatively clear. The hormonal and reproductive picture is more complicated, and precision matters here. Menstrual regularity. Clinical observations and some studies report improved cycle regularity in women with PCOS taking GLP-1 medications. This is plausible and encouraging, but it is likely at least partly mediated by weight loss rather than a direct drug effect, and the evidence base is not yet large or rigorous enough to draw firm conclusions. Androgens. Some studies show reductions in free androgen index and total testosterone. A meta-analysis, however, found no statistically significant change in free testosterone compared to placebo or metformin. The evidence is genuinely mixed, and any androgen-lowering effect may be partly or entirely explained by weight loss. Ovulation and fertility. Early evidence suggests that GLP-1 medications may improve ovulation and pregnancy rates in women with PCOS. Most studies in this area have small sample sizes, and weight loss alone improves fertility in this population, making it difficult to isolate the drug's contribution. Ovarian cysts. Some reports describe reductions, but this has not been well studied. Whether GLP-1 receptor agonists improve reproductive outcomes beyond what weight loss alone would achieve is not established. That question remains open.

Gastrointestinal effects. Nausea, vomiting, diarrhea, and dizziness are the most commonly reported side effects, typically most pronounced during dose escalation. For many people they improve over time, but they can be significant enough to affect daily life. Pancreatitis. This is a rare but documented risk worth discussing with your prescriber, particularly if you have other risk factors. Injection logistics. Most formulations are weekly subcutaneous injections requiring a titration period, meaning you start at a low dose and increase gradually over weeks to months. Cost and access. These medications are expensive, often running into hundreds of dollars per month without insurance coverage. Because PCOS is not an approved indication, coverage for off-label use is not guaranteed and can require significant effort to obtain. Weight regain after stopping. Studies show that weight regain after discontinuing GLP-1 medications is common and can be substantial, often occurring within months to a year of stopping. For women with PCOS, symptoms tied to weight and insulin resistance are likely to return as well. These are not short-course medications. If they are working, they are likely long-term medications, with real consequences for cost, logistics, and planning.

Oral contraceptive absorption. GLP-1 receptor agonists slow gastric emptying, which can reduce how well oral contraceptive pills are absorbed. Tirzepatide has a stronger effect on gastric emptying than semaglutide, making this concern especially relevant for women taking tirzepatide. During initiation and dose changes, barrier contraception or a non-oral hormonal method (such as an IUD, implant, or patch) is recommended. Pregnancy is a contraindication. GLP-1 receptor agonists should not be used during pregnancy. Safety data in humans is limited, and these medications are not considered safe for use while pregnant. Washout period before conception. A period off the medication before attempting to conceive is recommended. The recommended duration varies by drug, so this conversation should happen with your prescriber well before you plan to try. Pregnancy exposure data. Some observational reports have raised questions about risks if exposure occurs near conception. Larger registry data have been more reassuring, but the overall evidence base remains limited. Your prescriber's guidance matters here.

Most clinical trials of GLP-1 medications in PCOS are short-term. Long-term data specific to this population are limited, many studies have small sample sizes, and few include PCOS-specific subgroup analyses within larger trials. The central unresolved question is whether GLP-1 medications improve hormonal and reproductive outcomes through a direct mechanism, or whether the benefits are largely explained by weight loss. Preclinical studies in animals suggest possible direct anti-inflammatory effects on the ovaries, but human evidence for this is lacking. There are also no head-to-head trials comparing GLP-1 receptor agonists to metformin specifically for PCOS reproductive outcomes, and the populations studied may not reflect the full diversity of women with PCOS, including women with lean PCOS or women from different ethnic backgrounds who may have different metabolic profiles. These gaps do not mean the medications are not useful. They mean the evidence is still developing, and claims about what these drugs can do for PCOS should be held with some caution.

Given the evidence gaps and the practical considerations above, these are the questions worth raising before starting a GLP-1 medication for PCOS.

Do you currently meet the criteria for a GLP-1 prescription (obesity, insulin resistance, type 2 diabetes), or would this be off-label for PCOS alone?

How does this fit alongside your existing PCOS treatments, such as metformin, oral contraceptives, or lifestyle interventions?

What is your contraception plan, and is your current method affected by GLP-1 medications?

What is your reproductive timeline? If you are planning a pregnancy, timing and washout periods need to be part of the conversation now.

What does success look like for you specifically, whether that is weight, cycle regularity, androgen symptoms, or fertility, and how will you and your clinician track progress?

What happens if you stop the medication? Do you have realistic expectations about weight regain and symptom recurrence?

What will this cost, and is your insurance likely to cover it given that PCOS is not an approved indication?

GLP-1 receptor agonists are a legitimate and increasingly used tool for women with PCOS who have metabolic comorbidities. The evidence for weight loss and improved insulin resistance is well-supported. The evidence for reproductive and hormonal benefits is promising but not fully established, and it is not yet clear how much of that benefit is due to the medication itself versus the weight loss it produces. These medications are not a cure for PCOS, and they are not appropriate for every woman with the condition. Cost, side effects, contraception, and the likelihood of long-term use all deserve a direct conversation before starting.